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Summary The c-erbB-2 product is thought to be a unique and useful target for antibody therapy of cancers
overexpressing the c-erbB-2 gene. In vitro and in vivo anti-tumour effects of a humanised antibody against the
extracellular domain of the c-erbB-2 gene product, rhu4D5, were examined. Rhu4D5 was less effective than its
murine counterpart, mu4D5, for the direct antiproliferative activity against the c-erbB-2-overexpressing SK-
BR-3 cell line. In vivo treatment of severe combined immunodeficient (SCID) mice carrying the c-erbB-2-
overexpressing 4-1ST human gastric carcinoma xenograft with rhu4D5 revealed that the recombinant protein
had potent anti-tumour activity. Furthermore, cytotoxicity of human peripheral blood mononuclear cells
against 4-1ST was significantly augmented with rhu4D5, but not with mu4D5. These results indicate that
rhu4D5 might perform better in patients than predicted from preclinical studies.
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The c-erbB-2/HER-2 proto-oncogene encodes a receptor-type
tyrosine kinase (Yarden and Ullrich, 1988) related to, but
distinct from, the epidermal growth factor receptor (Coussens
et al., 1985; Yamamoto et al., 1986). The cell surface protein
consists of extracellular, transmembrane and intracellular
domains, the latter possessing kinase activity capable of
autophosphorylation. Appreciable amplification and/or over-
expression of this gene has been demonstrated in a variety of
adenocarcinomas including breast, ovarian, lung and gastric
cancers (King et al., 1985; Yokota et al., 1986; Van de Vijver
et al., 1987; Slamon et al., 1989; Kern et al., 1990). However,
the expression of this gene in normal adult tissues is weak
(De Potter et al., 1989; Press et al., 1990). Therefore, the c-
erbB-2 product is thought to be a useful target for antibody
therapy of cancers overexpressing the c-erbB-2 gene.
Several series of murine monoclonal antibodies (MAbs)
directed against the extracellular domain of the c-erbB-2 gene
product have already been reported to have in vitro and in
vivo anti-tumour effects (Drebin et al., 1985; Hudziak et al.,
1989; Hancock et al., 1991; Tagliabue et al., 1991; Stancovski
et al., 1991; Harwerth et al., 1992; Kasprzyk et al., 1992).
However, human anti-mouse antibody response during
therapy would be a major limitation in the clinical
application of such murine MAbs (Schroff et al., 1985;
Shawler et al., 1985). Therefore, Carter and his colleagues
constructed a 'humanised' antibody containing only the
antigen-binding loops from a murine MAb against the
extracellular domain of the c-erbB-2 gene product and
human variable region framework residues plus IgG,
constant domains (Carter et al., 1992).
In this study, we investigated the in vitro and in vivo anti-
tumour effects ofthe humanised antibody in comparison with
its murine counterpart.
Materials and methods
Cell lines and xenotransplanted tumour lines
Human tumour cell lines, SK-BR-3, BT474, MDA-MB-453,
MCF7, ZR-75-1, KATO III and IMR-32 were obtained from
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the American Type Culture Collection (Rockville, MD, USA).
Human gastric cancer cell lines, MKN45 and MKN7 were
obtained from Mitsubishi Chemical Corporation, Yokohama
Research Center (Yokohama, Japan). All cell lines except
MKN7 were maintained in RPMI-1640 medium with 10%
heat-inactivated fetal bovine serum (FBS; Flow Laboratory,
McLean, VA, USA). MKN7 was maintained in Ham's F-12
medium plus Dulbecco's modified Eagle medium (1: 1, v/v).
Human gastric carcinoma xenografts, 4-1ST and St-15, were
maintained by serial inoculation in Balb/cA nude mice.
Antibodies
A murine MAb, mu4D5, recognising the extracellular domain
of the c-erbB-2 product was generated by Fendly et al. (1990)
and supplied by Mitsubishi Chemical Corporation. A
humanised MAb, rhu4D5, was constructed from mu4D5 by
molecular engineering (Carter et al., 1992) and was also
provided by Mitsubishi Chemical Corporation. A class-
matched murine MAb that recognised the surface antigen
of hepatitis B virus, HBs, and an IgG, subclass human
immunoglobulin (Sigma, St. Louis, MO, USA) were used as
control antibodies.
Animals
Balb/cA-nu mice were obtained from Clea Japan (Tokyo,
Japan). CB-17-scid mice were gifts from Dr Bosma (Fox Case
Cancer Center, Philadelphia, PA, USA) and bred in our
animal quarters. They were maintained under specific
pathogen-free conditions in accordance with the animal care
guidelines of the Central Institute for Experimental Animals.
The mice were used at 6-8 weeks of age.
FACS analysis of c-erbB-2 protein expression
Cells were suspended in 1% (v/v) FBS in phosphate-buffered
saline (PBS). The cells (1 x 106 ml-1) were incubated for
60 min on ice with 1 ,ug of either 4D5 or control antibodies.
The cells were then washed twice, resuspended in 0.1 ml of
1% FBS/PBS and incubated with 12.5,ug of FITC-
conjugated F (ab')2 fragments of goat anti-mouse or anti-
human IgG (Orgaton Teknica-Cappel, Malvern, PA, USA)
for 45 min on ice. After being washed twice with 1% FBS/PBS, the cells were resuspended in 1 ml of assay buffer and
analysed using a FACScan cell sorter (Becton Dickinson,
Mountain View, CA, USA).
Proliferation assays
To examine in vitro effects of the MAbs on proliferation of
the human tumour cell lines, MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide] assay was used as
previously described by Mosmann (1983). Briefly, the cells
were cultured for 3 days with various concentrations of the
anti-c-erbB-2 antibodies, mu4D5 and rhu4D5, in 96-well flat-
bottom microplates. MTT (Sigma) solution (final concentra-
tion, 0.5 mg ml-') was added to the wells and the plates were
incubated at 37°C for 5 h. Then, acid-isopropanol was added
to the wells. The plates of triplicate samples were read on a
microelisa reader (SLT Labinstruments, Salzburg, Austria)
using a wavelength of 570 nm to determine relative cell
proliferation (per cent of control).
Antibody-dependent cell-mediated cytotoxicity (ADCC)
Freshly isolated peripheral blood mononuclear cells (PBMC)
from normal donors and spleen cells of Balb/cA-nu mice
were serially diluted into 96-well round-bottom microplates
with various dilutions of the antibodies and 2500 per well of
target tumour cells. The cytotoxicity was determined by a
4 h 51Cr-release assay. Each assay was performed in
triplicate. Per cent cytotoxicity was calculated as described
previously (Tokuda et al., 1989). Some results were
expressed as lytic units per 106 cells, with one lytic unit
being the number of effector cells required to cause 30%
lysis of target cells. The exponential fit equation and per
cent lysis with four effector/target cell ratios within each
experiment were used to obtain the target cell survival curve
and to calculate the lytic units.
In some experiments, solid tumours in nude mice were
resected, finely dispersed using scissors, incubated in Hanks'
balanced salt solution containing 0.05% pronase (Boehringer
Mannheim, Germany), 0.02% collagenase type I (Sigma) and
0.02% DNAase I (Sigma) at 37°C for 30 min, and then
passed through a nylon mesh to prepare single-cell
suspensions to be used as a target for ADCC assays.
In vivo anti-tumour assay
Effects on the tumours in the exponential growth phase were
examined by a previously described method (Inaba et al.,
1988), in which nude mice were used instead of SCID mice.
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In brief, a tumour fragment was subcutaneously inoculated
into the right flank of SCID mice. Tumour size was measured
twice a week with calipers, and tumour volume was
calculated according to the formula; tumour volume
(mm3) =length x (width)2x 1/2. Mice were randomly divided
into experimental groups when each tumour had reached a
palpable size (100- 300 mm3), and antibodies were injected
intravenously. Per cent tumour volume ratio of treated mice
to control mice (%T/C) was calculated for statistical analysis.
Statistical analysis
Wilcoxon's signed rank test and Spearman's rank correlation
test and the Mann-Whitney U-test were used for statistical
analysis.
Results
The binding of rhu4D5 to the c-erbB-2 protein was first
examined by flow cytometry and compared with that of
mu4D5. Figure 1 summarises all the FACS data obtained
from cell lines with rhu4D5 and mu4D5. No significant
difference was observed between rhu4D5 and mu4D5
(Wilcoxon's signed rank test). IMR-32, which is a human
glioma cell line with negative c-erbB-2 expression, was
negative for both rhu4D5 and mu4D5.
The antiproliferative activity of the two antibodies was
tested on a c-erbB-2-overexpressing human breast carcinoma
cell line, SK-BR-3, by MTT assay. At concentrations ranging
between 0.2 and 100 jug ml-' mu4D5 inhibited the growth of
SK-BR-3 slightly more strongly than rhu4D5 (Figure 2).
ADCC against SK-BR-3 of human PBMC with rhu4D5
and of murine splenocytes with mu4D5 was increased
dependent on the dose of both antibodies reaching a plateau
at more than 0.1jIg ml- (data not shown). Thus, 1 Mg ml-1
of the antibodies was used in subsequent experiments.
Cytotoxicity ofhuman PBMC against a variety ofc-erbB-2-
positive human tumourcell lines was significantly augmentedin
the presence ofrhu4D5 (Figure 3), but the extent ofkilling was
not correlated with the level of the c-erbB-2 expression (see
Figure 1) (correlation coefficient=0.25, P=0.066 by Spear-
man's test). Cytotoxicity against c-erbB-2-negative IMR-32
was not changed in the presence or absence ofthe antibody.
The anti-tumour effects of rhu4D5 were examined in vivo
in SCID mice transplanted with human gastric cancer 4-1ST
and St-15. As reported previously (Ohnishi et al., 1995), the
4-1ST tumour was found to express large amounts of the c-
erbB-2 protein at a similar level to SK-BR-3 by immunoblot-
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Figure 1 Reactivity of rhu4D5 and mu4D5 and with human
tumour cell lines by FACS analysis. Peak fluorescence intensity
represents peak intensity in the presence of rhu4D5 (M) or
mu4D5 (L=Z) minus background peak intensity with control
antibodies. There was no significant difference in reactivity
between rhu4D5 and mu4D5 in the paired Wilcoxon's test.
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Figure 2 Anti-proliferative effects ofrhu4D5 and mu4D5 on SK-
BR-3 as measured by MTT assay. The values represent the per
cent relative cell proliferation+s.d. The growth inhibitory effect
of rhu4D5 ( ) on SK-BR-3 was significantly less than that of
mu4D5 (- - -). Asterisks indicate significant differences in the
Mann-Whitney U-test (P<0.05).
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ting and Northern analyses, whereas the St-15 tumour was
found to express the c-erbB-2 protein at an undetectable
level.
SCID mice bearing 4-1ST or St-15 tumours were treated
with a single intravenous administration of 36 mg kg-' of
rhu4D5 or human IgG, when the tumour volume reached
100-300 mm3. Even 4 days after treatment, %T/C of 4-1ST
was significantly reduced to 50%. However, %T/C of St-15
was more than 100%. The difference in %T/C between 4-1ST
and St-15 was significant by the Mann-Whitney U-test
(Figure 4). On the other hand, mu4D5 was more potent in
inhibiting the growth of the 4-1ST xenograft (Figure 5).
To examine a role of ADCC in SCID mice treated with
rhu4D5 and mu4D5, 4-1ST tumour cells were cultured for a
short period and used as targets for ADCC assays. As shown
in Figure 6, cytotoxicity of murine splenocytes was not
augmented with mu4D5, whereas cytotoxicity of human
PBMC was strongly augmented by rhu4D5.
Discussion
The c-erbB-2 product is thought to be a unique and useful
target for antibody therapy of cancers overexpressing the c-
erbB-2 gene. Several series of murine MAbs directed against
the extracellular domain of the c-erbB-2 gene product have
been developed and examined to reveal their anti-tumour
effects, mainly in vitro. However, human anti-mouse antibody
response during therapy would be a major limitation on the
clinical application of such murine MAbs. Therefore, a
BT474
MCF7
MUA-MB-453
Li-75 1
MKN7
MKN45
KATOIII
IMR-32
humanised antibody against the c-erbB-2 gene product is
expected to be useful in clinical trials if its anti-tumour effects
in vitro and in vivo are similar to those of its murine
counterpart.
As Carter and his colleagues designed rhu4D5 to bind its
antigen 3-fold more tightly than mu4D5 by molecular
modelling (Carter et al., 1992), our flow cytometry analyses
revealed that the binding of rhu4D5 to the surface molecule
of the c-erbB-2 product was comparable with that of mu4D5.
In vitro anti-proliferative activity of rhu4D5 against SK-BR-3
was also comparable with that of mu4D5 in the MTT assay
as mentioned by Carter. Rhu4D5 was less potent in inhibiting
the growth of 4-1ST xenografts in SCID mice. However,
ADCC assays with rhu4D5 showed cytotoxicity against a
variety of human tumour cell lines overexpressing the c-erbB-
2 product. The extent of killing was not correlated with the
level of the c-erbB-2 expression. This was however not
surprising since susceptibility of the tumour cells to other
cytotoxic functions such as spontaneous cytotoxicity was
variable. Cytotoxicity of human PBMC against 4-1ST was
significantly augmented with rhu4D5, but not with mu4D5.
Thus, rhu4D5 may be predicted to have greater anti-tumour
potency in clinical trials than mu4D5.
There have been no published reports on in vivo anti-
tumour effects of humanised antibodies against the c-erbB-2
products, although rhu4D5 is currently undergoing evalua-
tion in the treatment of patients with breast cancer (Baselga
et al., 1995). Our preclinical study of rhu4D5 using SCID
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Figure 3 Cytotoxicity of human PBMC in the presence ( ) or
absence (LI) of rhu4D5 against various human tumour cell
lines. The values represent lytic units per 106 cells.
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Figure 5 In vivo anti-tumour effects of rhu4D5 ( ) and
mu4D5 (- - -) against 4-1ST transplanted in SCID mice. Both
MAbs were given i.v. at a dose of 36mgkg-1 on day 0. The
values represent mean %T/C+s.d. Asterisks indicate significant
differences in the Mann-Whitney U-test (P<0.005).
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Figure 4 In vivo effects of rhu4D5 on 4-1ST ( ) and St-15
(-
- -) transplanted in SCID mice. Rhu4D5 was given i.v. at a
dose of 36mgkg-1 on day 0. The values represent mean %T/
C+s.d. Asterisks indicate significant differences in the Mann-
Whitney U-test (*,P<0.05; **,P<0.005).
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Figure 6 ADCC activity of human PBMC ( ) and murine
splenocytes (-
- -) against 4-1ST tumour cells with rhu4D5 (0),
mu4D5 (A), human IgG, (0) and murine anti-HBs MAb (A).
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mice clearly demonstrated in vivo anti-tumour effects even
without human effector cells. although rhu4D5 was less
effective than mu4D5. Since ADCC activity of munrne
splenocytes With rhu4D5 against 4-1ST was similar to that
with mu4D5. the difference might be partlv owing to the
difference in the anti-proliferative actiVity. It was also likely
that in SCID mice. the biodistribution of a murine antibody
was altered less than that of a humanised antibody. In fact.
the elimiination half-life of a human monoclonal antibody
was much shorter than that of a murine monoclonal antibody
when administered to mice (Larson et al.. 1983: McCabe et
al.. 1988). Because the cvtotoxicitv of human PBMCs with
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